This transition is expected to expand patient access and increase adoption of GLP-1-based therapies
M.ZhangD.et al
At Rivas Medical Weight Loss we advise patients to avoid DIY cost-cutting
Psychometric analyses are ongoing and results will be ready for presentation at ISOQOL 2025
Comorbidities specific to OSA such as hypertension, hyperlipidemia, diabetes, cardiovascular disease, chronic obstructive pulmonary disease (COPD), depression, gastroesophageal reflux disease, metabolic disorders, somnolence, and stroke were identified using appropriate ICD-10 codes
For example, a research article found that 25% to 39% of the total weight lost while taking GLP-1s comes from muscle mass